Technical Analysis for FULC - Fulcrum Therapeutics, Inc.

Grade Last Price % Change Price Change
B 9.60 0.52% 0.05
FULC closed up 0.52 percent on Friday, February 23, 2024, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 7
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
NR7 Range Contraction 0.52%
Wide Bands Range Expansion 0.52%
Overbought Stochastic Strength 0.52%
180 Bullish Setup Bullish Swing Setup 0.52%
Slingshot Bullish Bullish Swing Setup 0.52%
Wide Bands Range Expansion 0.52%

   Recent Intraday Alerts

Alert Time
Possible NR7 3 days ago
Down 1% 3 days ago
Fell Below Previous Day's Low 3 days ago
Up 2% 3 days ago
Up 1% 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Hemoglobin Progressive Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy

Is FULC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.895
52 Week Low 2.25
Average Volume 646,837
200-Day Moving Average 4.83
50-Day Moving Average 7.38
20-Day Moving Average 8.52
10-Day Moving Average 9.34
Average True Range 0.51
RSI (14) 71.18
ADX 54.71
+DI 29.34
-DI 7.16
Chandelier Exit (Long, 3 ATRs) 8.36
Chandelier Exit (Short, 3 ATRs) 8.19
Upper Bollinger Bands 10.30
Lower Bollinger Band 6.74
Percent B (%b) 0.8
BandWidth 41.85
MACD Line 0.70
MACD Signal Line 0.65
MACD Histogram 0.0558
Fundamentals Value
Market Cap 593.5 Million
Num Shares 61.8 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -5.78
Price-to-Sales 208.91
Price-to-Book 2.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.10
Resistance 3 (R3) 10.09 9.93 10.01
Resistance 2 (R2) 9.93 9.80 9.93 9.98
Resistance 1 (R1) 9.76 9.72 9.85 9.77 9.96
Pivot Point 9.60 9.60 9.64 9.60 9.60
Support 1 (S1) 9.43 9.47 9.52 9.44 9.24
Support 2 (S2) 9.27 9.39 9.27 9.22
Support 3 (S3) 9.10 9.27 9.19
Support 4 (S4) 9.11